Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Core Insights - Fortress Biotech, Inc. and its subsidiary Cyprium Therapeutics announced the sale of Cyprium's Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million, marking a significant corporate transaction for both entities [1][2] Financial Impact - Fortress expects to receive over $100 million from the PRV sale, which will enhance its financial flexibility for business development and advancing its portfolio [2] - Cyprium is eligible for tiered royalties on net sales of ZYCUBO® and up to approximately $128 million in aggregate sales milestones from Sentynl Therapeutics [3] Product Development and Approvals - Fortress' portfolio has achieved three FDA approvals in the last 15 months for products Emrosi™, UNLOXCYT™, and ZYCUBO® [2] - ZYCUBO® was approved by the FDA on January 12, 2026, for the treatment of Menkes disease in pediatric patients [4] Corporate Structure and Strategy - Cyprium is a majority-owned subsidiary of Fortress, focusing on novel therapies for Menkes disease and related disorders [4] - Fortress operates with a model aimed at acquiring and advancing biopharmaceutical assets to enhance long-term shareholder value through various revenue streams [5]